Headquarters: 777 Old Saw Mill River Road
Tarrytown, NY 10591
CEO: Leonard Schleifer, M.D.
Stock Symbol: REGN
Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has
product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma,
atopic dermatitis, pain, cancer, and infectious diseases.
The company's main products are EYLEA, Dupixent and Libtayo.
Corporate offices are based in Tarrytown, NY with manufacturing facility in Rensselaer, NY.
In 2019, Regeneron reported total revenues of $7.86 billion, up 17% from the previous year, and net income of $2.11 billion. The company spent $3.03 billion for research and development in 2019.
For 2019, net sales of EYLEA in the United States were $4.64 billion.
Regeneron has over 8,100 employees worldwide including over 700 with a PhD, MD. or PharmD degree.
"Regeneron had a very productive 2019 marked by strong commercial growth for our core franchises, significant pipeline and regulatory progress, and positive financial results," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "In 2020, we are focused on driving continued growth with EYLEA, Dupixent, and Libtayo and anticipate several new regulatory approvals and submissions across our portfolio. Our expanding pipeline of innovative and complementary immuno-oncology therapies continues to advance, and we feel confident that we are positioned to bring new breakthroughs to cancer patients and be a leader in this rapidly evolving field."
Leonard Schleifer, M.D., Ph.D., a young neurologist and assistant professor at Cornell University Medical College, establishes the company in 1988 based on the principle that dedication to strong science would lead to important new medicines. His two co-founders are nationally-known scientists Drs. Alfred Gilman, Len's Ph.D. thesis advisor at the University of Virginia, and Dr. Eric Shooter. Drs. Gilman and Shooter recruit other leading scientists to join the company s scientific advisory board to help guide the young company. The company is named Regeneron because of the intention to focus on the use of gene technology to regenerate neurons. The first $1 million is raised from Merrill Lynch Venture Capital, Inc.
The company went public on Nasdaq stock market in 1991.
In 2011, Regeneron files for regulatory approval of EYLEA (aflibercept) Injection in February, receives FDA approval in November, and immediately makes the drug available in the U.S.
In 2012, FDA approves ZALTRAP for metastatic colorectal cancer.